Year: 2021

Extended agreement will also support Maltese telco’s plans to develop further its 5G offerings to consumer and business customers and assist its international expansion drive BIRKIRKARA, Malta and JERSEY CITY, N.J., Nov. 17, 2021 (GLOBE NEWSWIRE) — Malta-based telecoms operator Melita Limited has extended its relationship with Amdocs (NASDAQ: DOX), a leading provider of software and services to communications and media companies, in an agreement that will enable Melita to expand its range of IoT and 5G offerings for both consumer and business customers. Under the deal, Amdocs is providing charging solutions to help Melita create differentiated services and business models leveraging Melita’s 5G network. Amdocs will also deliver additional improvements to Melita’s customer data management, systems security, quality engineering and...

Innovative global intellectual property protector and producer to advocate fairness for content owners, fight online piracy in sixth most populated country NEW BOSTON, N.H., Nov. 17, 2021 (GLOBE NEWSWIRE) — Intellectual property protection and Identity as a Service (IdaaS) firm American Films, Inc. (OTC: AMFL) today announced that it has launched business operations in Brazil. Working through its sister entity Facterra, the company has established an office in São Paolo, the largest city in Latin America. Facterra has also begun working in Brazil’s capital city of Brasilia to combat online piracy in the sixth most populous country in the world, advocating for greater intellectual property protections. “Our expansion into Latin America is another important step in the growth of our intellectual property protection strategies,” said...

Primary objectives: to assess the effect of vafidemstat to address negative and cognitive symptoms in schizophrenia Phase IIb adaptive trial planning to enroll 100 patients Second Phase IIb study of vafidemstat in CNS disordersMADRID, Spain and CAMBRIDGE, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) — Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today the enrollment of the first patient in the EVOLUTION Phase IIb clinical trial with vafidemstat in patients with schizophrenia, at the Vall d’Hebrón Hospital in Barcelona, Spain. EVOLUTION (EudraCT No.: 2021-000350-26) is a multicenter, double-blind, randomized, placebo-controlled, 24-week Phase IIb trial to evaluate the efficacy and safety...

  Opdateret prospekt for Investeringsforeningen Gudme Raaschou offentliggøres dags dato. Prospektet er overordnet set opdateret med en række generelle præciseringer. Der er endvidere foretaget tilpasninger i afsnittet om investeringsrådgivning, herunder ny beskrivelse af resultathonorar i afdeling Europæiske Ejendomsaktier. Herudover skifter afdeling US High Yield benchmark pr. 1. januar 2022. Prospektet er vedhæftet og findes på foreningens hjemmeside www.lsinvest.dk. Eventuelle henvendelser vedrørende denne meddelelse kan rettes til undertegnede på telefon 3814 6600. Med venlig hilsen Invest Administration A/S Niels Erik EberhardDirektørAttachmentGR Prospekt November 2021 Clean

NEW YORK and CLEVELAND, Nov. 17, 2021 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that information about the company’s ABO-102 pivotal Transpher A study in Sanfilippo syndrome type A (MPS IIIA) will be presented at the 14th International Congress of Inborn Errors of Metabolism (ICIEM). The meeting will take place virtually and at the Hilton Sydney in Sydney, Australia on November 21-23, 2021. The oral presentation titled, “Interim results of Transpher A, a multicenter, single-dose, phase 1/2 clinical trial of ABO-102 gene therapy for Sanfilippo syndrome type A (mucopolysaccharidosis IIIA),” will be presented by Dr. Nicholas Smith, Department of Neurology and Clinical Neurophysiology, Women’s and Children’s Hospital. The presentation includes new...